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infusion solutions stored at room temperature with light (ambient) or at 21C to 81C without light
(refrigeration).
Methods: Telavancin was reconstituted with 5% dextrose, 0.9% normal saline, or sterile water (15 mg/mL).
Infusion solutions at 0.6 and 8.0 mg/mL were prepared in ViaFlex (polyvinyl chloride) IV bags (Baxter
International Inc, Deerﬁeld, Illinois) using 5% dextrose, 0.9% normal saline, or lactated Ringer’s solution.
Chemical stability was evaluated for up to 14 days under refrigeration and for up to 3 days under ambient
conditions. Telavancin concentration and degradant levels were determined using a stability-indicating
HPLC method. Solutions were subjected to microbial-challenge testing for up to 48 hours (ambient) or
for up to 6 days (refrigeration).
Results: All reconstituted or infused telavancin solutions met the prespeciﬁed stability acceptance
criteria after 2 days under ambient and minimum 7 days under refrigeration. Following inoculation
with gram-positive and gram-negative microorganisms, telavancin infusion solutions stored under
ambient conditions reduced or inhibited populations of all organisms up to 48 hours, except for Serratia
marcescens, which exhibited growth of 40.5 log10 after 12 hours. All refrigerated samples inhibited or
reduced bacterial populations up to 6 days.
Conclusions: These results are supportive of a total hold time for reconstituted telavancin in vials plus the
time in IV infusion solutions in polyvinyl chloride bags to not exceed 12 hours under ambient conditions
and 7 days under refrigeration.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The spread of methicillin-resistant Staphylococcus aureus (MRSA)
as well as the emergence of strains with intermediate or full
resistance to vancomycin has created an urgent need for novel
antimicrobial agents with activity against resistant strains of S. aureus.
Telavancin for injection is a once-daily injectable lipoglycopep-
tide antibiotic with a dual mechanism of action that combines
inhibition of cell wall synthesis and disruption of the functional
integrity of the bacterial cell membrane.1 It has shown bactericidal
activity against clinically important gram-positive pathogens,
including MRSA, streptococci, and VanB-type enterococci.2,3 InInc. This is an open access article u
heravance Biopharma US, Inc,Phase 3 clinical trials, telavancin achieved its objective for non-
inferiority to standard of care for treatment of complicated skin
and skin structure infections (cSSSI) and hospital-acquired and
ventilator-associated bacterial pneumonia caused by gram-
positive pathogens.4,5
Telavancin is approved in the United States for the treatment of
adults with cSSSI and hospital-acquired and ventilator-associated
bacterial pneumonia (HAP/VAP) caused by susceptible isolates of S
aureus when alternative treatments are not suitable. Telavancin is
approved in Europe for the treatment of adults with nosocomial
pneumonia, including VAP caused by MRSA and approved in
Canada for the treatment of adults with cSSSI caused by suscep-
tible gram-positive bacteria, including S aureus (both MRSA and
methicillin-susceptible strains).
Telavancin for injection formulation contains hydroxypropyl-β-
cyclodextrin and mannitol to enhance the solubility and stability.
Telavancin for injection is provided as sterile, lyophilized powdernder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of telavancin for injection intravenous (IV) solution in bags stored
at 201C were recently published6; however, there is no pub-
lished information on the stability of telavancin for injection after
reconstitution and dilution at refrigeration or room temperature
with lights (ambient). These guidelines would be useful for
infusion centers or hospital pharmacies where pharmacists rou-
tinely prepare large numbers of telavancin IV bags in advance so
that they are readily available for patient use. This study examined
the chemical stability and bacteriostatic/bactericidal properties of
telavancin for injection after reconstitution and storage in poly-
vinyl chloride (PVC) bags of IV infusion solutions at concentrations
simulating those used in clinical practice when stored under
refrigerated conditions (21C–81C without light) and under ambient
conditions (room temperature [201C–251C] with light) for up to
14 days.Samples and Methods
Chemicals and reagents
Telavancin for injection 250-mg (lot 1283200) and 750-mg (lots
1229527, 1229529, and 1229530) vials (Ben Venue Laboratories,
Inc, Bedford, Ohio) were used to prepare the samples. Sterile water
for injection (SWFI) (Baxter International Inc, Deerﬁeld, Illinois),
5% dextrose injection (D5W) (Baxter International Inc), 0.9%
sodium chloride injection (normal saline [NS]) (Baxter Interna-
tional Inc), Lactated Ringer’s solution (LR) (100 mL, 250 mL, or 500
mL) (Baxter International Inc), ViaFlex PVC IV bags (Baxter Interna-
tional Inc) and sterile syringes (30 cc and 60 cc) (Becton Dickinson,
Franklin Lakes, New Jersey) were obtained commercially. Acetoni-
trile was high-performance liquid chromatography (HPLC)-grade
or better (Burdick & Jackson, Muskegon, Michigan), and formic
acid was American Chemical Society reagent grade (EMD,
Gibbstown, New Jersey). All reagents were used without further
puriﬁcation. Puriﬁed water (analytical grade [resistivity of Z18
MΩ.cm]) was generated in-house (MilliQ Advantage A10; EMD
Millipore, Billerica, Massachusetts).
Sample preparation for chemical analysis
Samples of telavancin for injection were reconstituted in
triplicate with appropriate amounts of the reconstitution diluents
(D5W, SWFI, or NS) in the drug product vial with butyl rubber
stoppers to yield a telavancin concentration of 15 mg/mL for both
the 250 mg/vial and 750 mg/vial drug products. Vial reconstitution
to 15 mg/mL is described in the telavancin for injection label.
Intravenous infusion solutions at target concentrations of
0.6 and 8 mg/mL—which cover the full range of concentrations
to be used in clinical practice as speciﬁed on the label for
telavancin for injection—were prepared in triplicate by transfer-
ring the required amount of reconstituted telavancin solutions to
IV infusion bags of D5W, NS, or LR using sterile syringes. Samples
reconstituted with D5W and NS were further diluted with D5W
and NS, respectively, whereas samples reconstituted with SWFI
were subsequently diluted with D5W, NS, or LR. The IV infusion
bag target concentrations were calculated based on theoretical ﬁll
volumes of the IV bags; typical overﬁll volumes were not
estimated.
Test conditions and drug attributes tested
Storage conditions tested were room temperature (201C–251C)
with mixed standard laboratory ﬂuorescent light and nondirect
daylight from windows in the laboratory (ambient conditions), orat 21C to 81C without light (refrigerated conditions, uncovered).
Stability assessments for the reconstituted solutions in vials were
made at the outset for all sample solutions and at 0, 1, 3, and 7 days
for the refrigerated conditions, and at 0, 1, and 2 days for the
ambient conditions. For IV infusion solutions, the stability assess-
ments were at 0, 3, 7, and 14 days for the refrigerated conditions
and 0, 1, 2, and 3 days for the ambient conditions. The stability
analysis for the 2-day samples stored under ambient conditions
was only performed for samples that failed the acceptance criteria
at 3 days. The selection of the stability study duration was based
on the common practice at pharmacies and previous stability
results of telavancin reconstituted solutions.
The drug attributes tested and the corresponding acceptance
criteria were based on the US Food and Drug Administration-
approved speciﬁcation: visual appearance of dosage solution (con-
forms to USP o14), telavancin concentration by HPLC (90.0%–
110.0% of initial assay), level of degradant A by HPLC (r1.0% wt/
wt), level of degradant B (the primary degradation product of
telavancin) by HPLC (r3.0% wt/wt), and level of total degradation
products by HPLC (r4.0% wt/wt).
Telavancin concentration is expressed as milligrams per milli-
liter, whereas the degradant concentration is determined as the
weight of each degradant/the weight of telavancin free base (salt
form—telavancin hydrochloride) in the sample. Both of them are
determined by comparing external telavancin reference standards
injected during the HPLC analysis sequence. The response factors
of degradants were determined to be similar to those of telavancin
peak during the method validation, so the weight of each degra-
dant/the weight of telavancin free base determination is based on
the single reference standard of telavancin hydrochloride.
Physical attributes
The color and the clarity of the reconstituted and IV infusion
solutions were determined by visual inspection of singular sam-
ples. Determinations of pH were performed using a Seven Easy pH
meter (Mettler-Toledo International Inc, Columbus, Ohio).
HPLC analysis
A validated HPLC stability-indicating method analyzed telavan-
cin and its impurity/degradants. The HPLC instrumentation (1100
series HPLC; Agilent Technologies, Santa Clara, California, and
2695/2996 HPLC; Waters Corporation, Milford, Massachusetts)
included a C18 column (SunFire HPLC column 3.5 µm, C18, 150 
4.6 mm; Waters Corporation), maintained at 301C, a vacuum
degasser, an autosampler capable of maintaining temperatures at
51C, a solvent delivery system, a column oven compartment, a
diode-array detector, and Empower software (Empower Chroma-
tography Data System; Waters Corporation). The mobile phase
solutions consisted of acetonitrile:water:formic acid (2:98:0.05
vol/vol/vol) as mobile Phase A and acetonitrile:water:formic acid
(60:40:0.05 vol/vol/vol) as mobile Phase B at a ﬂow rate of 1 mL/
min. The mobile phase A of the HPLC gradient was set as follows:
0 minutes ¼ 90%, 20 minutes ¼ 85%, 30 minutes ¼ 80%, 50
minutes ¼ 60%, and 50.5 minutes ¼ 0% followed by 5 minutes
washout and equilibrating period. The injection volume of 80 mL
was used for all injections of standards and samples. Quantitation
was performed by integration of the peaks at a detection wave-
length of 230 nm for telavancin and its degradant peaks.
System suitability consisted of a relative standard deviation of
r1.0% of telavancin peak area from 6 consecutive replicate
injections (80 mL) of a system suitability solution, with tailing
factor of r3, theoretical plates of Z10,000, and resolution
between peak I and peak II of Z0.5, along with the relative
standard deviation of r1% of telavancin peak area from
Table I
Results of pH test for reconstituted solutions in vials.
Vial strength
(mg/vial)
Reconstituted
solution
Refrigerated* Ambient
conditions†
Initial 1 d 3 d 7 d Initial 1 d 2 d
250 SWFI 4.60 4.55 4.58 4.63 4.55 4.55 4.55
D5W 4.51 4.51 4.46 4.55 4.47 4.46 4.51
NS 4.66 4.65 4.63 4.58 4.67 4.65 4.63
750 SWFI 4.63 4.64 4.49 4.64 4.61 4.61 4.61
D5W 4.65 4.63 4.57 4.68 4.74 4.65 4.69
NS 4.69 4.71 4.60 4.78 4.71 4.70 4.78
D5W ¼ 5% dextrose injection; NS ¼ 0.9% sodium chloride injection (normal
saline); SWFI ¼ sterile water for injection.
n Stored at 21C to 81C without light.
† Room temperature with light.
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injection sequence.6
The HPLC method was validated in accordance with the
International Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use Q2 (R1).7
The detailed method validation information along with represen-
tative chromatograms that show retention times of degradant A
and B were also published.6Microbial challenge studies
Microbial challenge studies were performed by BioScreen Test-
ing Service, Inc (Torrance, California), according to a study protocol
approved by Theravance. Microbial cultures were prepared for
inoculation with 103 to 104 CFU/mL Pseudomonas aeruginosa (ATCC
9027), Escherichia coli (ATCC 8739), Serratia marcescens (ATCC
14041), Staphylococcus aureus (ATCC 6538), Candida albicans (ATCC
10231), Aspergillus niger (ATCC 1604), Staphylococcus epidermidis
(ATCC 700566), and vancomycin-resistant Enterococcus faecalis
(ATCC 51575).
Telavancin for injection 750-mg vials were reconstituted to 15
mg/mL with D5W, NS, or SWFI, respectively. Telavancin for
injection 250-mg vials were reconstituted to 15 mg/mL with
D5W, NS, or SWFI, respectively, and further diluted in IV bags
with D5W, NS, or LR to a target ﬁnal telavancin concentration of
0.6 mg/mL. All sample preparations for microbial challenge studies
were carried out in a Class 100 Laminar Flow Hood.
Reconstituted vial solutions and IV bag solutions were each
inoculated with organisms representing a worst-case challenge of
103 to 104 CFU/mL. Solutions were tested for up to 48 hours underTable II
Percent of initial telavancin concentration in the reconstituted solution in vials at differ
Vial strength
(mg/vial)
Reconstituted
solution
Percent of initial assay mean values*
Refrigerated†
Actual initial concentration (FBE
in mg/mL)
1 d 3
250 SWFI 15.17 (0.03) 100.1 (0.6) 1
D5W 15.23 (0.05) 100.1 (0.1) 1
NS 15.26 (0.05) 100.3 (0.1) 1
750 SWFI 15.23 (0.06) 101.5 (0.6) 1
D5W 14.92 (0.12) 101.4 (0.6) 1
NS 15.09 (0.08) 100.8 (0.1) 1
D5W ¼ 5% dextrose injection; FBE ¼ free base equivalent; NS ¼ 0.9% sodium chloride
n Values are presented as mean (SD) of triplicate determination.
† Stored at 21C to 81C without light.
‡ Room temperature with light.ambient conditions and 144 hours (6 days) under refrigerated
conditions. Samples stored under ambient conditions were col-
lected at time intervals of 0, 6, 8, 12, 24, and 48 hours. Samples
stored at refrigerated conditions were collected and tested at time
intervals of 0, 6, 8, 12, 24, 48, 72, and 144 hours. The speciﬁed
acceptance criterion was no increase in microbial growth 40.5 log
from the time zero count.Results
Chemical and physical stability of telavancin after reconstitution in a
vial
Following reconstitution of each vial, the solution appearance
was clear and essentially free of particulate matter.
The pH values of the reconstituted drug product solutions—
regardless of the dosage strength, reconstitution solution, time
point, or storage condition—was within the normal variation
between 4.46 and 4.78 (Table I).
All reconstituted drug product combinations met the prespeci-
ﬁed acceptance criteria with respect to the concentration of
telavancin (Table II), degradant B (Table III), degradant A, and
total degradants (degradant A þ degradant B). The levels of
degradant A and total degradants are not tabulated in detail,
because there are no signiﬁcant changes in the levels of degradant
A, and all were o0.2% wt/wt (compared with acceptance criterion
of r1.0% wt/wt) throughout the study in either condition for
reconstituted solutions (“signiﬁcant change” for a drug product is
deﬁned by International Conference on Harmonisation as a 5%
change in concentration from its initial values, or failure to meet
the acceptance criteria for potency, degradation products, appear-
ance, physical attributes, pH, and functionality test). Data on
degradant B show that this primary degradant increases with
time at both conditions; however, it remains within the accept-
ance criteria for at least 2 days under ambient conditions and for
7 days under refrigerated conditions, regardless of the type of
reconstitution solution. The changes in the concentration are
primarily caused by analytical variability and the increase of
degradant B; nevertheless, the values remain within the product
speciﬁcation acceptance criteria for the durations and conditions
tested.
Chemical/physical stability of telavancin with infusion solutions
The appearance for all infusion solutions was clear and essen-
tially free of particulate matter at all time points. The pH values ofent time points.
Ambient conditions‡
d 7 d Actual initial concentration (FBE
in mg/mL)
1 d 2 d
00.7 (0.2) 100.7 (0.5) 15.21 (0.13) 99.6 (0.7) 98.8 (0.3)
00.7 (0.6) 100.7 (0.4) 15.22 (0.09) 100.2 (0.9) 99.6 (0.7)
00.6 (0.3) 101.1 (0.1) 15.22 (0.15) 99.2 (0.1) 99.2 (0.2)
01.5 (0.2) 100.8 (0.1) 15.26 (0.03) 100.9 (0.1) 100.0 (0.2)
01.8 (0.6) 101.0 (0.6) 14.96 (0.03) 100.7 (0.5) 99.9 (0.2)
00.7 (0.2) 100.1 (0.3) 15.07 (0.08) 100.2 (0.5) 99.7 (0.6)
injection (normal saline); SWFI ¼ sterile water for injection.
Table III
Degradant B (% wt/wt) results of reconstituted solution in vials at different time
points.
Vial strength
(mg/vial)
Reconstituted
solution
Refrigerated* Ambient
conditions†
Initial 1 d 3 d 7 d Initial 1 d 2 d
250 SWFI 1.06 1.17 1.30 1.55 1.04 1.60 2.10
D5W 1.06 1.16 1.27 1.50 1.05 1.55 2.04
NS 1.12 1.15 1.24 1.38 1.12 1.48 1.86
750 SWFI 1.02 1.19 1.22 1.47 1.00 1.57 2.10
D5W 1.02 1.16 1.20 1.47 0.99 1.56 2.07
NS 1.06 1.18 1.17 1.43 1.08 1.53 1.95
D5W ¼ 5% dextrose injection; NS ¼ 0.9% sodium chloride injection (normal
saline); SWFI ¼ sterile water for injection.
n Stored at 21C to 81C without light.
† Room temperature with light.
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reconstitution solutions and IV solutions at different time points or
storage conditions are shown in Table IV. No signiﬁcant changes
over time were observed for all tested infusion solutions.
The concentrations of telavancin in IV infusion solutions held in
commercially available PVC IV bags at different time points are
shown in Table V. The telavancin concentrations of IV infusion
solution meet the prespeciﬁed speciﬁcation at all time points. Due
to the typical overﬁll (5%–15% in volume) of infusion solution bags,
the actual initial concentrations of reconstituted solutions are 5%
to 15% lower than the theoretical concentration.
The levels of degradant B in IV infusion solutions held in
commercially available PVC IV bags with different combinations
of reconstitution solutions and IV solutions are shown in Table VI.
The levels of degradant B for IV infusion solutions are within the
acceptance criteria of r3.0% after 3 days under ambient con-
ditions for all IV solutions, except when D5W is used as the IV
dosing solution at 0.6 mg/mL. In this case, the levels of degradant B
are within the acceptance criteria of r3.0% after 2 days under
ambient conditions. The levels of degradant A and total degradants
are not shown because there were no signiﬁcant changes.Microbial challenge hold time of telavancin in various solutions
Ambient conditions: Reconstituted solution in vials
Reconstituted telavancin for injection solutions were challenged
with yeast; mold; and gram-positive and gram-negative micro-
organisms including S. aureus, S. epidermidis, vancomycin-resistantTable IV
Results of pH testing for intravenous infusion solutions in polyvinyl chloride bags at dif
Reconstituted solution Dosing solution Dose strength (mg/mL) Refr
Initi
SWFI LR 0.6 5.53
SWFI D5W 0.6 5.33
SWFI NS 0.6 5.10
D5W D5W 0.6 5.43
NS NS 0.6 5.00
SWFI LR 8 5.11
SWFI D5W 8 4.71
SWFI NS 8 4.67
D5W D5W 8 4.62
NS NS 8 4.60
D5W ¼ 5% dextrose injection; LR ¼ Lactated Ringer’s injection; NS ¼ 0.9% sodium chlo
n Stored at 21C to 81C without light.
† Room temperature with light.E. faecalis, C. albicans, A. niger P aeruginosa, and E. coli to represent a
worst-case condition in the event of an inadvertent contamination
during the reconstitution or dilution of the product for infusion. The
results showed fungicidal, bactericidal, or bacteriostatic properties
(no growth or growth o0.5 log10) when stored under ambient
conditions for at least 48 hours, except for gram-negative organism
S. marcescens. The solution challenged with Serratia marcescens
showed a growth of 0.6 to 0.9 log10 at 48 hours in SWFI, NS, and
D5W; whereas there is no growth or growth o0.5 log10 at 0, 6, 8,
12, and 24 hours.
Ambient conditions: Solution in IV bags
Telavancin for injection reconstituted with D5W, NS, or SWFI
solutions that were further diluted in IV bags containing D5W, NS,
or LR were also challenged with the same microorganisms. The
results exhibited bactericidal or bacteriostatic properties for D5W
and NS IV bags stored under ambient conditions for at least 48
hours, except for S. marcescens, which showed a growth of 0.5 to
1.2 log10 at 24 and 48 hours, respectively; there was no growth or
growth o0.5 log10 at 0, 6, 8, and 12 hours. Telavancin for injection,
reconstituted with SWFI and diluted in a LR IV bag solution,
showed that all microorganisms grew 40.5 log10 at 24 and 48
hours but not at 0, 6, 8, and 12 hours.
Based on the microbial growth data of reconstituted vial
solutions and IV bag solutions stored under ambient conditions,
a maximum 12-hour hold period is justiﬁed.
Refrigerated conditions: Reconstituted solution in vials and solution in
IV bags
Test results for all refrigerated samples showed either stasis or
signiﬁcant logarithmic reductions in microbial populations over
the 144-hour (6-day) hold time. Based on the ﬂat or negative
slopes of the microbial populations over the challenge period, a
maximum 7-day hold period is justiﬁed.Discussion
The physical and chemical stability and microbial hold time of
telavancin for injection in therapeutic reconstituted solutions and
IV infusion solutions in PVC bags under conditions that reﬂect
typical hospital practices were evaluated in this study. The IV
infusion solutions tested in this study are those speciﬁed in the
label of telavancin for injection. These data establish a reference
for proper storage and handling of this drug product upon
reconstitution and dilution into PVC IV bags.ferent time points.
igerated* Ambient conditions†
al 3 d 7 d 14 d Initial 1 d 2 d 3 d
5.46 5.43 5.84 5.81 5.88 NT 5.68
4.73 4.92 5.09 5.20 4.83 5.03 4.81
4.88 5.14 5.21 5.12 4.90 NT 4.88
4.82 5.18 5.07 5.12 5.11 5.14 4.83
4.96 5.00 5.10 4.86 4.79 NT 4.94
5.05 5.13 5.17 5.09 5.06 NT 5.03
4.69 4.76 4.81 4.70 4.64 NT 4.64
4.75 4.81 4.90 4.73 4.64 NT 4.77
4.72 4.86 4.91 4.57 4.59 NT 4.71
4.78 4.80 4.94 4.63 4.60 NT 4.78
ride injection (normal saline); NT ¼ not tested; SWFI ¼ sterile water for injection.
Table V
Percent of initial assay mean values* in intravenous infusion solution in polyvinyl chloride bags at different time points
Reconstituted
solution
Dosing
solution
Refrigerated† Ambient conditions‡
Actual initial concentration§
(mg/mL)
3 d 7 d 14 d Actual initial concentration
(mg/mL)
1 d 2 d 3 d
SWFI LR 0.57 (0.00) 97.1 (1.1) 98.6 (0.5) 98.7 (0.8) 0.57 (0.00) 98.9 (1.1) NT 96.6 (0.6)
SWFI D5W 0.58 (0.01) 97.4 (0.9) 98.7 (1.3) 99.3 (1.3) 0.59 (0.02) 98.5 (2.5) 97.5
(3.1)
94.6 (3.9)
SWFI NS 0.58 (0.00) 95.4 (1.4) 97.8 (1.3) 99.0 (0.7) 0.59 (0.01) 98.3 (1.4) NT 94.6 (2.2)
D5W D5W 0.56 (0.01) 97.5 (1.0) 99.1 (2.0) 98.3 (1.2) 0.55 (0.00) 99.1 (0.6) 97.9
(0.5)
96.4 (0.2)
NS NS 0.57 (0.01) 95.4 (0.8) 98.6 (1.4) 99.0 (0.7) 0.58 (0.01) 99.7 (1.2) NT 95.8 (1.0)
SWFI LR 7.59 (0.05) 100.3 (0.7) 100.1 (0.5) 100.0 (0.7) 7.41 (0.05) 100.6 (0.8) NT 98.5 (1.1)
SWFI D5W 7.74 (0.08) 99.1 (0.9) 100.4 (1.0) 99.1 (1.2) 7.12 (0.13) 100.0 (1.4) NT 99.0 (1.8)
SWFI NS 7.53 (0.08) 101.1 (1.0) 100.9 (1.3) 100.4 (1.1) 7.64 (0.05) 99.9 (0.8) NT 98.9 (0.9)
D5W D5W 7.37 (0.07) 101.1 (0.9) 100.7 (0.6) 100.1 (1.1) 7.45 (0.04) 99.9 (0.5) NT 98.7 (0.9)
NS NS 7.23 (0.02) 101.9 (0.8) 101.4 (0.8) 100.5 (0.8) 7.50 (0.03) 98.9 (0.8) NT 97.5 (0.3)
D5W ¼ 5% dextrose injection; LR ¼ Lactated Ringer’s injection; NS ¼ 0.9% sodium chloride injection (normal saline); NT ¼ not tested; SWFI ¼ sterile water for injection.
n Values are presented as mean (SD) of triplicate determination.
† Stored at 21C to 81C without light.
‡ Room temperature with light.
§ Due to the typical overﬁll (5%–15% in volume) of infusion solution bags, the actual initial concentrations of reconstituted solutions are 5% to 15% lower than the
theoretical concentration.
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preservative is present in telavancin for injection, aseptic technique
must be strictly observed when preparing product for administration.Conclusions
The chemical and physical stability and microbial challenge
data reported here support a postconstitution hold time of 12
hours under ambient conditions and 7 days under refrigerated
conditions for both reconstituted telavancin for injection in a vial
and IV infusion solutions in a PVC IV bag when prepared with the
diluents tested in this study. The total time in the vial, plus the
time in the infusion bag, should not exceed 12 hours at room
temperature and 7 days under refrigeration at 21C to 81C.Acknowledgments
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1.38 1.62 1.90 1.12 1.55 NT 2.32
1.49 1.87 2.38 1.13 1.78 2.62‡ 3.18‡
1.51 1.79 2.23 1.11 1.72 NT 2.98
1.52 1.86 2.43 1.08 1.83 2.64‡ 3.20‡
1.56 1.80 2.27 1.16 1.77 NT 2.98
1.38 1.65 1.91 1.12 1.57 NT 2.60
1.45 1.69 2.10 1.08 1.66 NT 2.80
1.40 1.61 1.97 1.12 1.57 NT 2.59
1.42 1.70 2.09 1.08 1.62 NT 2.82
1.40 1.62 1.88 1.13 1.57 NT 2.54
ride injection (normal saline); NT ¼ not tested; SWFI ¼ sterile water for injection.
ts were analyzed.
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